The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson's disease in

F Giesert1, L Glasl2, A Zimprich2

  • 1Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Developmental Genetics, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany; Technische Universität München-Weihenstephan, Lehrstuhl für Entwicklungsgenetik, c/o Helmholtz Zentrum München, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany.

Insights

The Leucine-rich repeat kinase 2 (LRRK2) R1441C mutation in mice models early Parkinson's disease symptoms. This LRRK2 mutation causes specific deficits, not a general loss of function, making it a valuable preclinical model.

Area of Science:

  • Neuroscience
  • Genetics
  • Parkinson's Disease Research

Background:

  • Mutations in the Leucine-rich repeat kinase 2 (LRRK2) gene are linked to familial Parkinson's disease (PD).
  • Understanding the in vivo function of LRRK2 is crucial for developing effective PD treatments.

Purpose of the Study:

  • To investigate the in vivo function of the LRRK2 gene, specifically the R1441C mutation associated with PD.
  • To comprehensively analyze a novel LRRK2 R1441C knock-in mouse model throughout its lifespan.

Main Methods:

  • Generation of a mouse model with the endogenous LRRK2 R1441C point mutation.
  • Lifespan analysis and comparison with an existing LRRK2 knockdown mouse line.
  • Assessment of motor function, gait, olfaction, and neurodegeneration signs.

Main Results:

  • Neither LRRK2 R1441C nor LRRK2 knockdown mice showed severe motor deficits or neurodegeneration.
  • Homozygous LRRK2 R1441C mice exhibited prodromal PD phenotypes (impaired fine motor skills, gait, olfaction) in old age.
  • LRRK2 knockdown mice showed only marginal phenotypes, suggesting compensatory mechanisms.

Conclusions:

  • The LRRK2 R1441C mutation induces mutation-specific deficits rather than a general loss of function.
  • The LRRK2-R1441C knock-in mouse line serves as a valid preclinical model for the prodromal phase of Parkinson's disease.